Numerous studies have demonstrated the oncogenic role of MET overexpression in various malignancies, including: mediating chemoresistance in non-small cell lung cancer24, conferring tamoxifen resistance in breast cancer25, promoting gastric cancer progression26, and facilitating hepatocellular carcinoma initiation and metastasis27,28. The gene discussed is MET; the disease is hepatocellular carcinoma.